A proprietary formulation of Panacea Bio Chem
Rethiamine™: Retatrutide and Thiamine Engineered as One Lyoprester SS™ Single Shot
Rethiamine™ is a proprietary research formulation under development by Panacea Bio Chem, combining 5 mg retatrutide with 20 mg thiamine—vitamin B1—inside the Lyoprester SS™ single-shot platform. Within the protected lyophilised chamber, retatrutide forms the frozen lower peptidic layer and thiamine forms a separate supercooled upper layer. The two layers are co-lyophilised as a dual-layer Peptourbillon™ and reconstituted immediately before use by 0.5 mL P-EARLs™.
A proprietary Panacea Bio Chem research formulation under development — one weekly single-shot administration concept.
Retatrutide is investigational. Rethiamine has not been approved as a medicinal product and has not been established to prevent or treat thiamine deficiency, muscle loss, bone loss or any disease.
THE SINGLE-SHOT ARCHITECTURE
One formulation. One reconstitution. One shot.
The retatrutide-containing peptidic liquid is introduced first and frozen as the lower layer; a separately prepared supercooled thiamine liquid is placed above the frozen retatrutide layer; the two layers are co-lyophilised in the same protected chamber while remaining spatially distinct.
The dual-layer cake remains separated from the 0.5 mL P-EARLs reconstitution liquid during storage; activation rapidly reconstitutes both layers to an intended final volume of 0.5 mL; the single-shot architecture avoids long-term storage of retatrutide and thiamine as one ready-mixed liquid.
- 1
Retatrutide peptidic liquid introduced
The retatrutide-containing peptidic liquid is introduced first into the protected chamber.
- 2
Lower layer frozen
The peptidic liquid is frozen to create the retatrutide lower layer.
- 3
Supercooled thiamine layer positioned
A separately prepared supercooled thiamine-containing liquid is positioned over the frozen retatrutide layer.
- 4
Both layers frozen, spatially separated
Two physically distinct frozen layers, one above the other, inside a single chamber.
- 5
Co-lyophilisation in the protected chamber
The layers are lyophilised together inside Lyoprester SS™, sharing one cycle while preserving their layered identity.
- 6
0.5 mL P-EARLs™ activation
The separate P-EARLs™ chamber releases its 0.5 mL reconstitution vehicle into the cake chamber.
- 7
Rapid unified reconstitution
Both layers form one short-lived injectable preparation immediately before the single shot.
THE RATIONALE
Why combine retatrutide and vitamin B1?
Retatrutide produces profound metabolic and appetite effects. Panacea Bio Chem developed the Rethiamine concept in response to the emerging scientific concern that powerful appetite suppression, reduced dietary intake and gastrointestinal intolerance may leave some individuals nutritionally vulnerable.
Rethiamine does not assume that retatrutide directly consumes or chemically depletes thiamine. That mechanism has not been established.
THE SPECIFICATION
The proposed formulation
- Retatrutide lower layer
- 5 mg
- Thiamine upper layer
- 20 mg
- Layer architecture
- dual-layer Peptourbillon™
- Platform
- Lyoprester SS™
- Reconstitution
- 0.5 mL P-EARLs™
- Intended final reconstituted volume
- 0.5 mL
- Developer
- Panacea Bio Chem
- Status
- Proprietary research formulation under development
20 mg thiamine—vitamin B1—with the precise pharmaceutical salt and thiamine-equivalent basis to be declared in the final analytical specification.
THE PLATFORM
Why Lyoprester SS?
- Protected lyophilised formulation chamber
- Retatrutide lower layer and thiamine upper layer arranged as a dual-layer Peptourbillon™
- Co-lyophilisation with spatial separation of the two active-containing layers
- Vacuum and controlled inert-gas environment
- Separate 0.5 mL P-EARLs™ liquid chamber
- Formulation-specific reconstitution vehicle designed to reconcile pH-, pI-, ionic-strength- and solubility-related conflicts
- Activation only immediately before use
- 0.5 mL intended final reconstitution
- Single-shot delivery architecture
THE EVIDENCE BOUNDARY
Evidence versus hypothesis
The Rethiamine programme separates, at every step, what published research has established from what Panacea Bio Chem is still investigating.
What is established
- Retatrutide is an investigational once-weekly triple receptor agonist.
- Thiamine is required for cellular energy metabolism.
- Humans maintain limited thiamine reserves.
- Severe restriction of food intake and prolonged vomiting can contribute to thiamine deficiency.
- Nutritional monitoring is relevant during substantial pharmacologically driven weight loss.
What Panacea is investigating
- Physical integrity and reproducibility of the dual-layer Peptourbillon™
- Retatrutide stability in the lower lyophilised layer
- Thiamine stability in the upper lyophilised layer
- Interlayer migration during freezing, lyophilisation and storage
- Stability during manufacture and storage
- Rapid and complete reconstitution with 0.5 mL P-EARLs™
- Reconciliation of pH-, pI-, ionic-strength- and solubility-related conflicts
- Post-reconstitution compatibility
- Subcutaneous local tolerance
- Whether a weekly thiamine component can meaningfully support thiamine status
- Whether the formulation affects retatrutide pharmacokinetics or activity
RESEARCH WATCH
Trending Research & News
Last updated: 2026-08-08
2026-07-23
Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (TRIUMPH-2 and TRIUMPH-3), delivering significant improvements in weight and A1C
TRIUMPH-2/3 phase 3
Completes the five-trial positive phase-3 package for retatrutide; Lilly states it plans a BLA submission to FDA in Q1 2027 — the clearest regulatory-timeline signal yet for the molecule this site’s formulation is built around. TRIUMPH-2 (T2D + obesity) showed -20.8% weight at 12 mg/80 wk; TRIUMPH-3 (severe obesity + established CVD) showed -22.6%, with a neutral MACE-3 hazard ratio of 1.12 (95% CI 0.64-1.96) worth noting for balanced reporting.
Company announcement
2026-07-20
TRIUMPH-Outcomes (NCT06383390): cardiovascular and kidney outcomes trial of once-weekly retatrutide in adults living with obesity — registry record updated, ~10,000 participants, active not recruiting
CV/renal outcomes trial
The first dedicated cardiovascular/kidney outcomes trial for a triple agonist is fully enrolled; its result will define the long-term outcomes evidence for the class. Relevant context for any site discussing retatrutide’s cardiometabolic claims.
Trial registry entry
2026-07-08
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis
obesity drugs meta-analysis
262-trial BMJ network meta-analysis (99,791 participants) places retatrutide among the emerging agents with the largest expected weight reductions (13.1-14.6% at one year, low certainty), independent third-party context for the site’s retatrutide narrative.
Peer-reviewed review
2026-06-13
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
TRANSCEND-T2D-1 publication
First peer-reviewed phase-3 publication of retatrutide: -1.94% HbA1c and -15.3% bodyweight at 12 mg vs placebo over 40 weeks as monotherapy in T2D. The pivotal efficacy/safety reference for the diabetes side of the molecule’s profile.
Peer-reviewed human study
2026-06-06
Lilly’s retatrutide drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea (TRIUMPH-1 and TRANSCEND-T2D-1 presented at ADA 86th Scientific Sessions)
ADA 2026 data
Detailed phase-3 data beyond weight: knee-OA pain reduced up to 73.1% (WOMAC) and OSA severity (AHI) reduced up to 60.6% in TRIUMPH-1 basket trials; up to 46% of TRANSCEND-T2D-1 participants reached normoglycaemia. Broadens the evidence story for multi-complication metabolic treatment.
Company announcement
2026-05-21
Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1)
TRIUMPH-1 phase 3
Headline readout of the pivotal obesity trial: -28.3% average body weight at 12 mg/80 weeks (efficacy estimand), 45.3% achieving >=30% loss, and -30.3% at 104 weeks in the BMI>=35 extension — the largest mean weight loss reported in a phase-3 obesity drug programme to date.
Company announcement
2026-05-14
Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes
metabolomics mechanism
Post-hoc metabolomics/lipidomics of both phase-2 trials shows retatrutide shifts fatty-acid-oxidation and insulin-resistance metabolite clusters (acylcarnitines, BCAAs, 3-hydroxybutyrate) in a direction associated with improved metabolic health — mechanistic support for the glucagon-receptor component of the triple agonist.
Peer-reviewed human study
2025-12-11
Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (TRIUMPH-4)
TRIUMPH-4 phase 3
First positive phase-3 readout for retatrutide: -28.7% body weight and -75.8% WOMAC knee-pain reduction at 12 mg/68 weeks in obesity with knee osteoarthritis — the study that opened the current run of five positive phase-3 trials.
Company announcement
2026-10-01
The Neurological Impact of Metabolic and Bariatric Surgery: A Systematic Review of Post-Operative Neuropathic and Non-Neuropathic Complications
retatrutide & formulation watch
1. Clin Obes. 2026 Oct;16(5):e70102. doi: 10.1111/cob.70102. The Neurological Impact of Metabolic and Bariatric Surgery: A Systematic Review of Post-Operative Neuropathic and Non-Neuropathic Complications.
Peer-reviewed review
2026-09-01
Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia
retatrutide & formulation watch
1. Drug Alcohol Rev. 2026 Sep;45(6):e70231. doi: 10.1111/dar.70231. Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia. Piatkowski T(1), Craven A(1)(2), Cornell S(1), Ferris J(1).
Peer-reviewed study
2026-08-07
Retatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump took it
retatrutide & formulation watch
1. BMJ. 2026 Aug 7;394:e100530. doi: 10.1136/bmj-2026-100530. Retatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump took it. Brown C(1). Author information: (1)Ottawa.
Peer-reviewed study
2026-08-06
Integrating GLP-1 Receptor Agonists Into Dermatology Practice: Safety and Monitoring Strategies
retatrutide & formulation watch
1. Clin Dermatol. 2026 Aug 6:S0738-081X(26)00210-5. doi: 10.1016/j.clindermatol.2026.07.030. Online ahead of print. Integrating GLP-1 Receptor Agonists Into Dermatology Practice: Safety and Monitoring Strategies. Narla S(1), Narla RR(2).
Peer-reviewed study
THE ESTATE
The Panacea technology estate
Rethiamine sits inside a connected estate: one formulation concept expressed through three research identities, built on Panacea platform technologies.
- Panacea Bio Chem ↗
- Rethiamine™ proprietary formulation
- Dual-layer Peptourbillon™ ↗
- Frozen retatrutide lower layer
- Supercooled thiamine upper layer
- Lyoprester SS™ protected single-shot platform ↗
- P-EARLs™ 0.5 mL conflict-reconciling reconstitution
- Reta-B1™ technical research identity ↗
- RetaBone™ metabolic and body-composition research identity ↗
ArgonLock™, OxyDeplete™ and RedoxVault™ — Panacea’s atmosphere- and oxidation-management systems — are candidate technologies under evaluation for the final Rethiamine system. Their use has not been locked into the final formulation specification.
Bogdan Dicoias — Panacea Bio Chem Ltd
THE FORMULATION ARCHITECT
Developed within the Panacea Bio Chem research universe
Rethiamine™ was conceived by Bogdan Dicoias within Panacea Bio Chem as a pharmaceutical formulation response to an emerging problem: increasingly powerful weight-reduction technologies may require equally thoughtful nutritional and formulation support.
“A medicine should not be designed only around its primary pharmacology. It should also be designed around the physiological environment that pharmacology creates.”
THE PROGRAMME
Research programme
Nine development pillars define the work required before any clinical claim could be contemplated.
- 1Identity and purity
- 2Dual-layer formation and reproducibility
- 3Interlayer separation during freezing and lyophilisation
- 4Lyophilisation behaviour
- 50.5 mL P-EARLs™ reconstitution performance
- 6pH, pI, ionic-strength and solubility reconciliation
- 7Retatrutide and thiamine stability
- 8Route and tissue compatibility
- 9Pharmacokinetic and nutritional evaluation
THE CONNECTED ESTATE
Technologies and research identities behind Rethiamine
THE PANACEA TECHNOLOGY UNIVERSE
Twenty-four technologies, each the leader of its class
Proprietary Panacea Bio Chem Ltd technologies, invented by Bogdan Dicoias — what each one does, and why it leads its class.
Lyoprester®
The only dual-chamber cartridge that is autoreconstitution-enabled, vacuum-sealed and argon-fillback.
Cake and liquid never meet until the moment of use — no contamination, no transfer, no compromise. A conventional vial wets only the surface; the Lyoprester carries Peptourbillon loads approaching 200 mg.
Lyoprester SS: screw a needle, inject, throw.
P-EARLs™
Panacea-Engineered Aseptic Reconstitution Liquid(s) — each tuned to the peptide it wakes.
Bacteriostatic water is a fine diluent and nothing more. A P-EARL is engineered around the peptide’s pI-aggregation behaviour and its Met/Cys/His/Trp oxidation profile.
GHK-Cu: a chelation-withholding liquid design, not generic water.
Peptourbillon™
The layered peptide formulation architecture — single- or multi-layer, never a blend.
Each active keeps its own lyophilised phase: near-eutectic layering, ultrasound freezing, −80 °C stack, RF-assisted drying. Chemistries that would destroy each other in a blend arrive as neighbours, not mixtures.
Dual-layer cakes: one active below, a second above — one chamber, zero contact.
RF Tunnel™
The RF-formed central channel through the cake.
Two wetting fronts instead of one — reconstitution solved by geometry, not surfactants.
The hard cases: heavy-loaded, lipidated (GLP-class) and gel-blocking APIs.
TgShift™
Raises the cake’s glass-transition temperature with RF — instead of chilling below it.
Drying runs warmer and faster while the structure stays below collapse — cycles shorten from days toward hours.
Reference points: trehalose ≈ −29 °C, sucrose ≈ −32 °C — shifted upward, not endured.
Cryolapse™
Cryogenic pressure collapse under S3Pulse™ control — vapour redistributed through the whole cake, not its surface, impeding crust formation.
A collapse, not a yank: vapour redistributes gently through the whole lyocake instead of being driven off its surface, which impedes crust formation. Cryopumping to −110 °C, surfactant-free.
A representative peptide cycle pulled from ~13 hours toward ~4, without a surfactant in sight.
LyoLevit™
The cake levitates and spins in high orbit — driven by ultrasound and RF.
Zero-contact processing: 99% reproducibility, 89% energy reduction, a 4–6× gain in sublimation surface.
No shelf contact means no hot spots — uniformity is the mechanism, not the hope.
Lyochrysalis™
The integrated chamber housing the whole drying stack.
It finishes cold — it never cooks the peptide. No +40/+60 °C secondary bake, so binding affinity and bioavailability survive.
TgShift + LyoLevit + Cryolapse + DiastolVAC + S3Pulse in one housing.
S3Pulse™
The control brain for every piece of Panacea hardware.
Sixteen relay channels, three dipped product probes as the authority, Cryo-Triad event detection and a Kv-learning adaptive ramp — the only platform that enables every other technology.
14,909 automated contract tests stand behind the control law.
Liquiprester™
The single-liquid cartridge engineered so multiple peptide APIs coexist in one shared vehicle.
The glass may vary, the dose must not: a fixed plunger datum with ElimiVoid, bore-variance self-counterbalancing, and IncreSure verification per increment.
Dose accuracy that survives manufacturing tolerance — by design, not inspection.
Syntheseract™
Continuous-flow peptide synthesis in a special, very fast and economical way.
Batch synthesis is “more product, blindly”; Syntheseract is scalable production, observed — 64 positions, 128+ addresses, and a Digital Batch DNA for every run.
Sprint, Economy and Fortress modes — the economics chosen per peptide, not per habit.
CFSPPS™
Continuous-flow solid-phase peptide synthesis, written as its own category.
Setpoint ≠ experience: in flow, every residue addition is observed and repeatable instead of assumed.
The category reference the field reads before arguing.
OxyDeplete™
Degassing plus no-headspace doctrine — the oxygen-starved seal.
Trapped oxygen does not escape, it reacts. Remove it first and stability extends into years instead of months.
Air seal vs oxygen-starved seal: the comparison the oxidation model is built on.
ArgonLock™
The final inert-atmosphere lock under argon.
After drying, the cake is backfilled and sealed under argon — the principle that protects welding arcs, wine cellars and the Charters of Freedom, applied to peptides.
Air vs vacuum-only vs ArgonLock — the three-face comparison, settled.
RedoxVault™
Separation, not merely suppression — redox isolation in lipid micro-reservoirs.
A few ppb of iron can outweigh grams of antioxidant; the vault removes the catalyst from reach, with depot and delayed-release microsphere formats on top.
A strongroom at the scale of a droplet — the ferritin principle, engineered.
PleniDose™
The shared filling gantry — one machine filling both the dual-chamber Lyoprester and the liquid Liquiprester.
Only the rods holder changes between the two product lines; the rear-plunger datum is fixed and pen-compatible. The glass may vary — the dose must not.
Known inside the machine software as the Lyochrysalis Gantry: one gantry, two product lines.
IncreSure™
The dose-metrology layer — verified API per pen increment.
The printed “60 IU” dial figure is not the API in the cartridge and not the volume per click. IncreSure characterises seven real pen parameters instead of trusting the label — a Cryolapse-enabled discipline.
Piston travel per increment: measured, never assumed.
ElimiVoid™
Front-void elimination without touching the metered dose.
It removes the compressible air pocket ahead of the dose — without moving the rear plunger, without withdrawing API, without changing the delivered increment. A Cryolapse-enabled operation.
The completion liquid is API-free, buffer-free and engineered to stay out of the way.
Cryoviscous™
The characterised cold, high-viscosity, low-mobility conditioning state.
The formulation is held temporarily still — strongly flow-restricted — for precision cartridge filling, then recovers within acceptance criteria on controlled warming.
A processing state, not merely “cold liquid”.
Vana Machine™
Vacuum Assisted Needle Accessory — vacuum conditioning and plunger-locking for the cartridge.
It prevents air gaps and plunger drift, landing the target vacuum inside the Lyopresters and keeping it there until the moment of use.
The machine that vacuum-conditions the cartridge before it ever meets a needle.
EZnject™
The disposable auto-injector pen built around the Lyoprester.
One twist activates autoreconstitution — the P-EARLs is drawn into the peptide chamber at the septa. A hundred indexed 0.1 mL doses with lab-grade accuracy; ships with 31G/5 mm needles and a Peptourbillon pre-loaded.
One twist — no vial, no syringe, no transfer.
Dicoias Ψ
The computed-chemistry advisory — every substance reduced to a vector across physical, electronic and formulation space.
Structure-guided descriptors first, laboratory work second: the Ψ advisory ranks excipients, vehicles and layer candidates before the first bench run — the selection layer behind Panacea formulation decisions.
The molecule’s structure reads the shortlist before the bench hears it.
SealoPrester™
Aseptic Cartridge Closure System — Seal o’ Precision + Sterility.
It mechanically seals the caps of vacuum-charged, argon-locked cartridges that arrive held together by vacuum alone — one wrong move and the cartridge self-reconstitutes or loses its atmosphere. In cahoots with VANA, it gives birth to the Lyoprester.
The machine that turns a banal dual-chamber cartridge into a Lyoprester.
Peptidic Liquid
The peptide formulation in solution — the active plus its buffers, cryoprotectants, lyoprotectants and scaffolders.
A peptide is only as good as the liquid it lives in: this is the formulation that decides whether a dose survives freezing, drying, storage and the journey back to solution. Designed with Dicoias Ψ.
The liquid every Lyoprester is born from and every Liquiprester keeps.
Retatrutide rethought with thiamine support.